Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial

The multi-center, randomized, open-label, phase III trial discussed in the present study was performed to compare the clinical outcomes of nedaplatin (NDP) plus paclitaxel, and carboplatin (CBP) plus paclitaxel for the treatment of epithelial ovarian cancer (EOC). In the current study, 182 patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Lett
Hlavní autoři: Li, Li, Zhuang, Qingqing, Cao, Zeyi, Yin, Rutie, Zhu, Yaping, Zhu, Lirong, Xie, Xing, Zhang, Youzhong, Wu, Qiang, Zheng, Jianhua, Zhou, Qi, Li, Xiaoping, Wu, Lingying, Feng, Youji, Wang, Changyu
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2018
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5796383/
https://ncbi.nlm.nih.gov/pubmed/29467885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2018.7761
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky